Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBlue Cross Blue Shield - Oklahoma homocysteine tes…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB067

    Testing of Homocysteine Metabolism-Related Conditions

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLAB067 alerts

    Get alerted when Policy CPCPLAB067 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Blue Cross Blue Shield of Oklahoma reimbursement criteria for laboratory testing related to homocysteine metabolism (including newborn screening and plasma testing) and applies to providers submitting claims under BCBSOK plans.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyTesting of Homocysteine Metabolism-Related Conditions
    Policy CodePolicy CPCPLAB067
    Change TypeRemovals and literature update
    Effective DateMay 1, 2026
    Last ReviewJan 12, 2026
    Next Review Date
    Key ActionProviders must submit accurate documentation and use valid HIPAA-approved codes; claims may require additional documentation upon request.
    SourceLink
    POLICY UPDATE CHANGES

    For the diagnosis of phenotype variants of classic homocystinuria due to CBS deficiency, the pyridoxine (B6) challenge test may be reimbursable.

    Code 84207 was removed from the procedure/code list.

    Document updated with literature review and references revised.

    3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    reimbursable newborn screening/diagnostic scenarios listed
    1explicitly non-reimbursable test (plasma free homocysteine)
    1age-specific note for >18 years reimbursable testing
    multipleliterature and guideline references cited

    Reimbursement Criteria

    Reimbursement criteria — homocysteine metabolism testing

    Reimbursement criteria for testing related to homocysteine metabolism:

    ALL of the following

    • ANY of the following

      • Quantitative plasma amino acids analysis and/or plasma or urine total homocysteine analysis
      • Screening from dried blood spots (newborn screening)
      • Screening for hypermethioninemia in dried blood spots

    ALL of the following

    • ANY of the following

      • Repeat dried blood specimen submitted to the newborn screening program
      • Quantitative plasma amino acids analysis
      • Plasma total homocysteine analysis
    Plasma total homocysteine testing for adults (age > 18 years) is covered with criteria when used for evaluation or monitoring of suspected or confirmed CBS deficiency.
    Exclusion: Plasma free homocysteine testing is not covered (not reimbursable).

    Procedure Codes and Screening Follow-up

    Procedure codes (not exhaustive)CPT
    84207Removed from policy/code list
    Newborn methionine cut-off follow-up — required actions
    Action when initial methionine exceeds cut-offRepeat dried blood specimen submitted to the newborn screening program, or perform quantitative plasma amino acids and plasma total homocysteine; these follow‑up tests may be reimbursable.
    Trigger for follow‑upInitial newborn screening test result exceeds the methionine cut‑off level.
    Specimen options for follow‑upEither a repeat dried blood spot submitted to the newborn screening program or a venous specimen for quantitative plasma amino acids and plasma total homocysteine.
    Reimbursement stanceFollow‑up testing in these situations may be reimbursable subject to plan terms and verification.

    Documentation and Claims Submission

    Documentation Required

    Documentation, coding and claim review requirements

    Providers are responsible for submission of accurate documentation of services performed and must submit claims using valid HIPAA‑approved code sets and appropriate industry coding guidelines. Claims are subject to code edit protocols and claim review and may require additional documentation upon request.

    • Submit claims using valid code combinations from HIPAA‑approved code sets (eg, CPT, HCPCS, ICD‑10).
    • Code claims according to industry standard coding guidelines (eg, UB, AMA CPT, CMS NCCI edits).
    • Be prepared to provide additional documentation upon request for claim review.

    Key Test Definitions

    Total homocysteine (plasma) — notes
    DefinitionPlasma total homocysteine: measurement of total homocysteine in plasma used for evaluation of suspected homocystinuria (CBS deficiency) and for monitoring therapy in adults.
    Reimbursable scenariosMay be reimbursable for newborn screening (as plasma or urine total homocysteine), for follow‑up when methionine exceeds cut‑off, and for individuals >18 years with suspected or confirmed CBS deficiency (monitoring).
    Specimen typePlasma (also referenced: plasma or urine for newborn screening).
    Age note>18 years: plasma total homocysteine testing may be reimbursable for evaluation and therapy monitoring of suspected/confirmed CBS deficiency.
    Plasma free homocysteine — coverage exclusion
    Coverage determination
    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyTesting of Homocysteine Metabolism-Related Conditions
    Policy CodePolicy CPCPLAB067
    Change TypeRemovals and literature update
    Effective DateMay 1, 2026
    Last ReviewJan 12, 2026
    Next Review Date
    Key ActionProviders must submit accurate documentation and use valid HIPAA-approved codes; claims may require additional documentation upon request.
    SourceLink
    On This Page
    Reimbursement CriteriaProcedure Codes and Screening Follow-upDocumentation and Claims SubmissionKey Test Definitions
    Plasma free homocysteine testing is not reimbursable under this policy.
    Policy placementExplicit exclusion listed in Reimbursement Information item 4.
    Implication for claimsClaims for plasma free homocysteine testing are not covered and may be denied unless other covered testing is performed per policy criteria.